Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
about
Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV InfectionAssociation Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug ReactionNew treatment strategies for HIV-positive cancer patients undergoing antiblastic chemotherapy.Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus.Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Pharmacogenomic biomarkers for personalized cancer treatment.Tumour and patient factors in renal cell carcinoma-towards personalized therapy.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors.Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma.Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing
P2860
Q26749811-B417DACF-C304-43A9-9164-65DC95E6CEE9Q28550377-95BFDB61-DF59-42D6-9727-CD23C4A33F44Q30244166-F200D993-E8FE-41DB-9BEB-F191DBE24F41Q31102468-84AC6537-361E-4A87-B8BA-EB4062E95054Q33418378-416C0BE9-943F-4539-B201-DF7C1337C1C0Q33419367-40DE7C73-4222-4109-8531-17DD1A87E281Q33437427-6335AE32-5B91-4235-AD50-D0DC4638A121Q35063752-B134390F-BDE3-46C0-8199-D58842E2108DQ35921573-FF1CDAEC-0F1C-443D-BB05-5D625C54972CQ37387563-AF4343F6-C03B-4A5C-95C0-3ACB13D22CE3Q37650644-CCCC63B4-94A4-4903-95E8-D079F1CA5F01Q38187646-8ED9937C-5B20-4762-9359-C70CA7C88F61Q38207943-9A660460-DFC5-4A4F-96DD-4786D1609A19Q38262008-AF66CA23-4ACB-4DA0-A49B-82C52EC08C4CQ38418649-28BFD61A-E182-402F-AEFE-B83AAD000335Q38627885-6E1F87F0-E6E6-44CC-A9DB-021DB23BA2B7Q38720430-68CEF16D-738B-4B68-8D9E-50639DD746B9Q40875500-3177D688-62D4-4BF7-8078-C6638C369C36Q48306032-7892D11C-F2A0-487F-8F4C-BD247BE88335Q49997360-E60324AD-5893-4804-AB74-C9235D8F302DQ53581485-C2103071-99A6-47BB-A7FF-1BB37F9C1566Q54119194-D589BAE0-8B22-42CB-BAD8-64BAE8132556Q58050534-7B63FFF6-987F-4C7D-92B7-9E1FFD56B865
P2860
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacogenetic determinants a ...... renal cell carcinoma patients.
@ast
Pharmacogenetic determinants a ...... renal cell carcinoma patients.
@en
type
label
Pharmacogenetic determinants a ...... renal cell carcinoma patients.
@ast
Pharmacogenetic determinants a ...... renal cell carcinoma patients.
@en
prefLabel
Pharmacogenetic determinants a ...... renal cell carcinoma patients.
@ast
Pharmacogenetic determinants a ...... renal cell carcinoma patients.
@en
P2093
P2860
P50
P1476
Pharmacogenetic determinants a ...... renal cell carcinoma patients
@en
P2093
Hye Ryun Kim
Hyo Song Kim
Hyung Soon Park
Ji Hyun Lee
Sun Min Lim
Woo Sun Kwon
Yusuke Tanigawara
P2860
P2888
P304
P356
10.1007/S00280-013-2258-Y
P577
2013-09-08T00:00:00Z
P5875
P6179
1005580462